BioCentury
ARTICLE | Company News

Ipsogen SAS, INSERM, Institut Gustave Roussy, Assistance Publique - Hopitaux de Paris deal

April 10, 2006 7:00 AM UTC

The institute, hospital and INSERM granted Ipsogen exclusive worldwide rights to use a mutant form of the JAK2 gene to develop diagnostics for myeloproliferative disorders. Financial terms were not d...